Ginkgo Bioworks Q3 2026 Earnings: Losses Narrow Despite a 6% Revenue Decline

Ginkgo Bioworks (NYSE: DNA) reported Q3 2026 revenue of $27.7 million, down 6% from $29.4 million a year earlier, while GAAP loss per share from continuing operations improved to $0.64 from $1.32. The continuing-operations net loss narrowed to $41.0 million from $73.4 million, and the adjusted EBITDA loss fell to $22 million from $53 million as expenses declined. Quarterly cash burn was $27 million, with available cash and marketable securities totaling $285 million at September 30.

Core Financial Results

Revenue remained below the prior-year level, although it increased sequentially from approximately $20 million in Q2 2026. The more consequential change was the cost structure: total operating expenses declined by $40.3 million, more than offsetting the $1.7 million revenue decrease and substantially narrowing the operating loss.

Adjusted EBITDA is a non-GAAP measure. Other income also decreased to $2.4 million from $9.0 million, but this was outweighed by lower operating expenses.

Business and Segment Performance

Ginkgo now organizes its commercial strategy around two offerings built on the same autonomous-laboratory platform: Autonomous Labs Equipment and Cloud Lab Services. The company continues to report one financial segment, Cell Engineering, and did not disclose separate revenue for the two offerings.

The main Autonomous Labs development was Ginkgo’s first sale of an autonomous lab to Novo for its new research site in Waltham, Massachusetts. The company also disclosed an ARPA-H GIVE subcontract worth up to $17.5 million and cited previously announced lab commissions involving Caltech, the University of Maryland, Northwestern and MIT Media Lab.

Cloud Lab added 22 ADME customers during Q3, including 20 first-time Ginkgo customers. Takeda, Argenx, Lundbeck and AbbVie formed an antibody developability consortium, while GSK, Novartis and Biogen signed additional work. Ginkgo also said OpenAI is using Cloud Lab for AI data generation. These customer and contract announcements indicate commercial activity, but the company did not specify how much Q3 revenue they generated.

Profitability, Cash Flow and the Balance Sheet

The narrower quarterly loss was mainly expense-driven. Research and development expense declined to $40.9 million from $69.4 million, while general and administrative expense fell to $28.6 million from $37.0 million. Carrying costs for excess space remained substantial at $14.0 million, compared with $14.3 million a year earlier.

Ginkgo ended September with $84.5 million in cash and cash equivalents and $200.9 million in marketable securities, for total available resources of approximately $285.4 million. That was down from approximately $422.6 million at the end of 2025. The company also reported $27 million of Q3 cash burn.

During the first nine months of 2026, Ginkgo raised $23.8 million in gross proceeds through its at-the-market share offering. Its weighted-average common shares outstanding increased approximately 15% year over year to 64.0 million in Q3.

Accounting Losses Improved Faster Than Cash Flow

For the first nine months of 2026, the net loss from continuing operations narrowed by $35.5 million to $174.4 million. However, cash used by continuing operations increased by $5.4 million to $117.0 million, showing that the accounting improvement had not yet translated into better continuing-operations cash flow.

A reduction of $14.3 million in accounts payable and accrued liabilities—compared with a $17.4 million increase in the prior-year period—was a notable cash-flow headwind. Stock-based compensation also declined to $31.1 million from $51.2 million, reducing the noncash addback used to reconcile the net loss to operating cash flow. Consolidated operating cash use improved modestly to $119.3 million from $123.4 million because discontinued operations consumed less cash.

Full-Year Guidance

Ginkgo reaffirmed its full-year 2026 total cash-burn outlook. The company did not provide nine-month cash burn under the same non-GAAP definition, so the guidance should not be compared directly with GAAP operating cash flow.

Recent Insider Transactions

The six-month insider summary showed 238,866 shares purchased across seven transactions and 137,584 shares sold across nine transactions, resulting in net purchases of 101,282 shares. The most recent transactions with a clearly disclosed direction and value were all sales; this filing activity alone does not establish insiders’ views about the company’s prospects.

Four additional records dated October 16 were excluded because the supplied data did not identify a transaction direction, price or value.

Risks Investors Need to Watch

• Revenue has not returned to year-over-year growth. Q3 revenue declined 6%, while revenue for the first nine months fell approximately 37% to $67.3 million. New customer activity must convert into recognized revenue to stabilize the top line.
• Cash consumption remains material. Ginkgo reported $27 million of quarterly cash burn, and continuing operations used more cash during the first nine months despite a narrower accounting loss.
• Contract announcements do not guarantee immediate revenue. The ARPA-H subcontract is worth up to $17.5 million, while contract ceilings, lab commissions and customer signings may depend on execution, milestones and timing.
• Government funding and commercialization are important to the strategy. Changes in federal priorities, budgets or project timing could affect autonomous-lab deployments. At the same time, excess-space costs remain a burden on the cost structure.
• Additional financing can dilute existing shareholders. Ginkgo used its at-the-market offering during the first nine months, while the quarterly weighted-average share count increased approximately 15% year over year.

Summary

Ginkgo’s Q3 2026 improvement came primarily from lower expenses rather than renewed year-over-year revenue growth. Autonomous-lab deals and Cloud Lab customer additions provide potential sources of future revenue, but the central questions are how quickly those activities convert into sales, whether continuing-operations cash flow begins to improve and whether Ginkgo can remain within its full-year cash-burn range.